208 related articles for article (PubMed ID: 25113767)
1. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
Campigotto F; Weller E
J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
[TBL] [Abstract][Full Text] [Related]
2. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
Rosen K; Prasad V; Chen EY
Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
[TBL] [Abstract][Full Text] [Related]
3. The role of censoring on progression free survival: oncologist discretion advised.
Prasad V; Bilal U
Eur J Cancer; 2015 Nov; 51(16):2269-71. PubMed ID: 26259493
[TBL] [Abstract][Full Text] [Related]
4. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials.
Lesan V; Olivier T; Prasad V
Eur J Cancer; 2024 May; 202():114022. PubMed ID: 38547775
[TBL] [Abstract][Full Text] [Related]
5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
6. Informative censoring of surrogate end-point data in phase 3 oncology trials.
Gilboa S; Pras Y; Mataraso A; Bomze D; Markel G; Meirson T
Eur J Cancer; 2021 Aug; 153():190-202. PubMed ID: 34186504
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring.
Martini A; Yu M; Raggi D; Joshi H; Fallara G; Montorsi F; Necchi A; Galsky MD
Cancer; 2022 Aug; 128(15):2892-2897. PubMed ID: 35553053
[TBL] [Abstract][Full Text] [Related]
8. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
9. Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).
Lengliné E; Baba J; de Boissieu P; Beaufils A; Desbiolles A; Diatta T; Cochat P; Chevret S
Eur J Cancer; 2024 Jun; 204():114047. PubMed ID: 38653034
[TBL] [Abstract][Full Text] [Related]
10. Alternatives to the Kaplan-Meier estimator of progression-free survival.
Zhang JJ; Sun Z; Yuan H; Wang M
Int J Biostat; 2020 Sep; 17(1):99-115. PubMed ID: 32892174
[TBL] [Abstract][Full Text] [Related]
11. Equal censoring but still informative: When the reasons for censoring differ between treatment arms.
Olivier T; Prasad V
Eur J Cancer; 2024 Apr; 201():113942. PubMed ID: 38382151
[TBL] [Abstract][Full Text] [Related]
12. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
13. Estimation of colorectal adenoma recurrence with dependent censoring.
Hsu CH; Long Q; Alberts DS
BMC Med Res Methodol; 2009 Sep; 9():66. PubMed ID: 19788750
[TBL] [Abstract][Full Text] [Related]
14. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
15. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
16. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.
Tanase T; Hamada C; Yoshino T; Ohtsu A
Anticancer Res; 2017 Oct; 37(10):5851-5855. PubMed ID: 28982911
[TBL] [Abstract][Full Text] [Related]
17. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.
Rufibach K; Beyersmann J; Friede T; Schmoor C; Stegherr R
Trials; 2024 May; 25(1):353. PubMed ID: 38822392
[TBL] [Abstract][Full Text] [Related]
19. Fair comparisons of cause-specific and relative survival by accounting for the systematic removal of patients from risk-sets.
Wells M; Rutherford MJ; Lambert PC
Cancer Epidemiol; 2023 Oct; 86():102408. PubMed ID: 37591148
[TBL] [Abstract][Full Text] [Related]
20. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
Qi Y; Allen Ziegler KL; Hillman SL; Redman MW; Schild SE; Gandara DR; Adjei AA; Mandrekar SJ
Cancer; 2012 Nov; 118(21):5358-65. PubMed ID: 22434489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
